Loading…

Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism

Introduction/backgroundVitamin D deficiency further increases circulating parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism (pHPT), with potential detrimental effects on bone mass.MethodsThis was an observational clinical study in consecutive conservatively treated postme...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Connections 2012-07, Vol.1 (1), p.13-21
Main Authors: Rao, Ranganathan R, Randeva, Harpal S, Sankaranarayanan, Sailesh, Narashima, Murthy, Möhlig, Matthias, Mehanna, Hisham, Weickert, Martin O
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b316t-e6f162dfd2e6e093370e82fc14c21c8c5571e5271a70dddca6361bd08c5307cd3
cites
container_end_page 21
container_issue 1
container_start_page 13
container_title Endocrine Connections
container_volume 1
creator Rao, Ranganathan R
Randeva, Harpal S
Sankaranarayanan, Sailesh
Narashima, Murthy
Möhlig, Matthias
Mehanna, Hisham
Weickert, Martin O
description Introduction/backgroundVitamin D deficiency further increases circulating parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism (pHPT), with potential detrimental effects on bone mass.MethodsThis was an observational clinical study in consecutive conservatively treated postmenopausal women (n=40) with pHPT and coexistent 25-hydroxyvitamin D deficiency (25OHD ≤50 nmol/l (≤20 ng/ml)). Patients who showed an increase in serum 25OHD above the threshold of vitamin D deficiency (>50 nmol/l; n=28) using treatment with various commonly prescribed vitamin D preparations were, for the purposes of statistical analyses, allocated to the treatment group. Patients who were retrospectively identified as having received no treatment with vitamin D and/or remained vitamin D deficient were considered as non-responders/controls (n=12). Adjusted calcium (adjCa), PTH and 25OHD concentrations were monitored in all subjects up to 54 months (mean observation period of 18±2 months).ResultsProlonged increased vitamin D intake, regardless of the source (serum 25OHD, increase from 32.2±1.7 nmol/l at baseline to 136.4±11.6 nmol/l, P0.73). In contrast, serum PTH remained unchanged (15.8±2.6 vs 16.3±1.9 pmol/l, P=0.64) in patients who remained vitamin D deficient, with a significant difference between groups in changes of PTH (P=0.0003). Intrapartial correlation analyses showed an independent negative correlation of changes in 25OHD with PTH levels (ric=−0.41, P=0.014).ConclusionsProlonged treatment with vitamin D in various commonly prescribed preparations appeared to be safe and significantly reduced PTH levels by 21%.
doi_str_mv 10.1530/EC-12-0008
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3681316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>23781299</sourcerecordid><originalsourceid>FETCH-LOGICAL-b316t-e6f162dfd2e6e093370e82fc14c21c8c5571e5271a70dddca6361bd08c5307cd3</originalsourceid><addsrcrecordid>eNp9kM1LwzAYxoMoTuYu_gGSs1DNx5q2F0Hq_ICBHvTkIaRJukbapiTdxv57UzrHvHhJ8vL88rzv-wBwhdEtjim6W-QRJhFCKD0BFwTNs4gyPD89ek_AzPtvNCCYpRSdgwmhSYpJll2Ar3dna9uutIK906JvdNvDrekruDG9aEwLH2E4OusHyXZi7UUNtzYUI9Y50wi3g9Wu064TTvTVzlmjjG8uwVkpaq9n-3sKPp8WH_lLtHx7fs0fllFBMesjzUrMiCoV0UyjjNIE6ZSUEs8lwTKVcZxgHZMEiwQppaRgYatCoaBQlEhFp-B-9O3WRaOVDCs4UfP9ZNwKw_8qran4ym44ZSkOIwSDm9FAOuu90-XhL0Z8SJkvco4JHyIM8PVxtwP6m2kA0AgUxnppQk9TGin-8_wBTNuKpw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism</title><source>PubMed Central</source><creator>Rao, Ranganathan R ; Randeva, Harpal S ; Sankaranarayanan, Sailesh ; Narashima, Murthy ; Möhlig, Matthias ; Mehanna, Hisham ; Weickert, Martin O</creator><creatorcontrib>Rao, Ranganathan R ; Randeva, Harpal S ; Sankaranarayanan, Sailesh ; Narashima, Murthy ; Möhlig, Matthias ; Mehanna, Hisham ; Weickert, Martin O</creatorcontrib><description>Introduction/backgroundVitamin D deficiency further increases circulating parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism (pHPT), with potential detrimental effects on bone mass.MethodsThis was an observational clinical study in consecutive conservatively treated postmenopausal women (n=40) with pHPT and coexistent 25-hydroxyvitamin D deficiency (25OHD ≤50 nmol/l (≤20 ng/ml)). Patients who showed an increase in serum 25OHD above the threshold of vitamin D deficiency (&gt;50 nmol/l; n=28) using treatment with various commonly prescribed vitamin D preparations were, for the purposes of statistical analyses, allocated to the treatment group. Patients who were retrospectively identified as having received no treatment with vitamin D and/or remained vitamin D deficient were considered as non-responders/controls (n=12). Adjusted calcium (adjCa), PTH and 25OHD concentrations were monitored in all subjects up to 54 months (mean observation period of 18±2 months).ResultsProlonged increased vitamin D intake, regardless of the source (serum 25OHD, increase from 32.2±1.7 nmol/l at baseline to 136.4±11.6 nmol/l, P&lt;0.0001), significantly reduced serum PTH (13.3±1.1 vs 10.5±1.0 pmol/l, P=0.0001), with no adverse effects on adjCa levels (2.60±0.03 vs 2.60±0.02 mmol/l, P=0.77) and renal function tests (P&gt;0.73). In contrast, serum PTH remained unchanged (15.8±2.6 vs 16.3±1.9 pmol/l, P=0.64) in patients who remained vitamin D deficient, with a significant difference between groups in changes of PTH (P=0.0003). Intrapartial correlation analyses showed an independent negative correlation of changes in 25OHD with PTH levels (ric=−0.41, P=0.014).ConclusionsProlonged treatment with vitamin D in various commonly prescribed preparations appeared to be safe and significantly reduced PTH levels by 21%.</description><identifier>ISSN: 2049-3614</identifier><identifier>EISSN: 2049-3614</identifier><identifier>DOI: 10.1530/EC-12-0008</identifier><identifier>PMID: 23781299</identifier><language>eng</language><publisher>England: BioScientifica</publisher><ispartof>Endocrine Connections, 2012-07, Vol.1 (1), p.13-21</ispartof><rights>2012 The Authors. Published by BioScientifica Ltd.</rights><rights>2012 The Authors. Published by BioScientifica Ltd. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b316t-e6f162dfd2e6e093370e82fc14c21c8c5571e5271a70dddca6361bd08c5307cd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681316/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681316/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23781299$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rao, Ranganathan R</creatorcontrib><creatorcontrib>Randeva, Harpal S</creatorcontrib><creatorcontrib>Sankaranarayanan, Sailesh</creatorcontrib><creatorcontrib>Narashima, Murthy</creatorcontrib><creatorcontrib>Möhlig, Matthias</creatorcontrib><creatorcontrib>Mehanna, Hisham</creatorcontrib><creatorcontrib>Weickert, Martin O</creatorcontrib><title>Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism</title><title>Endocrine Connections</title><addtitle>Endocr Connect</addtitle><description>Introduction/backgroundVitamin D deficiency further increases circulating parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism (pHPT), with potential detrimental effects on bone mass.MethodsThis was an observational clinical study in consecutive conservatively treated postmenopausal women (n=40) with pHPT and coexistent 25-hydroxyvitamin D deficiency (25OHD ≤50 nmol/l (≤20 ng/ml)). Patients who showed an increase in serum 25OHD above the threshold of vitamin D deficiency (&gt;50 nmol/l; n=28) using treatment with various commonly prescribed vitamin D preparations were, for the purposes of statistical analyses, allocated to the treatment group. Patients who were retrospectively identified as having received no treatment with vitamin D and/or remained vitamin D deficient were considered as non-responders/controls (n=12). Adjusted calcium (adjCa), PTH and 25OHD concentrations were monitored in all subjects up to 54 months (mean observation period of 18±2 months).ResultsProlonged increased vitamin D intake, regardless of the source (serum 25OHD, increase from 32.2±1.7 nmol/l at baseline to 136.4±11.6 nmol/l, P&lt;0.0001), significantly reduced serum PTH (13.3±1.1 vs 10.5±1.0 pmol/l, P=0.0001), with no adverse effects on adjCa levels (2.60±0.03 vs 2.60±0.02 mmol/l, P=0.77) and renal function tests (P&gt;0.73). In contrast, serum PTH remained unchanged (15.8±2.6 vs 16.3±1.9 pmol/l, P=0.64) in patients who remained vitamin D deficient, with a significant difference between groups in changes of PTH (P=0.0003). Intrapartial correlation analyses showed an independent negative correlation of changes in 25OHD with PTH levels (ric=−0.41, P=0.014).ConclusionsProlonged treatment with vitamin D in various commonly prescribed preparations appeared to be safe and significantly reduced PTH levels by 21%.</description><issn>2049-3614</issn><issn>2049-3614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kM1LwzAYxoMoTuYu_gGSs1DNx5q2F0Hq_ICBHvTkIaRJukbapiTdxv57UzrHvHhJ8vL88rzv-wBwhdEtjim6W-QRJhFCKD0BFwTNs4gyPD89ek_AzPtvNCCYpRSdgwmhSYpJll2Ar3dna9uutIK906JvdNvDrekruDG9aEwLH2E4OusHyXZi7UUNtzYUI9Y50wi3g9Wu064TTvTVzlmjjG8uwVkpaq9n-3sKPp8WH_lLtHx7fs0fllFBMesjzUrMiCoV0UyjjNIE6ZSUEs8lwTKVcZxgHZMEiwQppaRgYatCoaBQlEhFp-B-9O3WRaOVDCs4UfP9ZNwKw_8qran4ym44ZSkOIwSDm9FAOuu90-XhL0Z8SJkvco4JHyIM8PVxtwP6m2kA0AgUxnppQk9TGin-8_wBTNuKpw</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Rao, Ranganathan R</creator><creator>Randeva, Harpal S</creator><creator>Sankaranarayanan, Sailesh</creator><creator>Narashima, Murthy</creator><creator>Möhlig, Matthias</creator><creator>Mehanna, Hisham</creator><creator>Weickert, Martin O</creator><general>BioScientifica</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20120701</creationdate><title>Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism</title><author>Rao, Ranganathan R ; Randeva, Harpal S ; Sankaranarayanan, Sailesh ; Narashima, Murthy ; Möhlig, Matthias ; Mehanna, Hisham ; Weickert, Martin O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b316t-e6f162dfd2e6e093370e82fc14c21c8c5571e5271a70dddca6361bd08c5307cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rao, Ranganathan R</creatorcontrib><creatorcontrib>Randeva, Harpal S</creatorcontrib><creatorcontrib>Sankaranarayanan, Sailesh</creatorcontrib><creatorcontrib>Narashima, Murthy</creatorcontrib><creatorcontrib>Möhlig, Matthias</creatorcontrib><creatorcontrib>Mehanna, Hisham</creatorcontrib><creatorcontrib>Weickert, Martin O</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Endocrine Connections</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rao, Ranganathan R</au><au>Randeva, Harpal S</au><au>Sankaranarayanan, Sailesh</au><au>Narashima, Murthy</au><au>Möhlig, Matthias</au><au>Mehanna, Hisham</au><au>Weickert, Martin O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism</atitle><jtitle>Endocrine Connections</jtitle><addtitle>Endocr Connect</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>1</volume><issue>1</issue><spage>13</spage><epage>21</epage><pages>13-21</pages><issn>2049-3614</issn><eissn>2049-3614</eissn><abstract>Introduction/backgroundVitamin D deficiency further increases circulating parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism (pHPT), with potential detrimental effects on bone mass.MethodsThis was an observational clinical study in consecutive conservatively treated postmenopausal women (n=40) with pHPT and coexistent 25-hydroxyvitamin D deficiency (25OHD ≤50 nmol/l (≤20 ng/ml)). Patients who showed an increase in serum 25OHD above the threshold of vitamin D deficiency (&gt;50 nmol/l; n=28) using treatment with various commonly prescribed vitamin D preparations were, for the purposes of statistical analyses, allocated to the treatment group. Patients who were retrospectively identified as having received no treatment with vitamin D and/or remained vitamin D deficient were considered as non-responders/controls (n=12). Adjusted calcium (adjCa), PTH and 25OHD concentrations were monitored in all subjects up to 54 months (mean observation period of 18±2 months).ResultsProlonged increased vitamin D intake, regardless of the source (serum 25OHD, increase from 32.2±1.7 nmol/l at baseline to 136.4±11.6 nmol/l, P&lt;0.0001), significantly reduced serum PTH (13.3±1.1 vs 10.5±1.0 pmol/l, P=0.0001), with no adverse effects on adjCa levels (2.60±0.03 vs 2.60±0.02 mmol/l, P=0.77) and renal function tests (P&gt;0.73). In contrast, serum PTH remained unchanged (15.8±2.6 vs 16.3±1.9 pmol/l, P=0.64) in patients who remained vitamin D deficient, with a significant difference between groups in changes of PTH (P=0.0003). Intrapartial correlation analyses showed an independent negative correlation of changes in 25OHD with PTH levels (ric=−0.41, P=0.014).ConclusionsProlonged treatment with vitamin D in various commonly prescribed preparations appeared to be safe and significantly reduced PTH levels by 21%.</abstract><cop>England</cop><pub>BioScientifica</pub><pmid>23781299</pmid><doi>10.1530/EC-12-0008</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2049-3614
ispartof Endocrine Connections, 2012-07, Vol.1 (1), p.13-21
issn 2049-3614
2049-3614
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3681316
source PubMed Central
title Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T16%3A12%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20treatment%20with%20vitamin%20D%20in%20postmenopausal%20women%20with%20primary%20hyperparathyroidism&rft.jtitle=Endocrine%20Connections&rft.au=Rao,%20Ranganathan%20R&rft.date=2012-07-01&rft.volume=1&rft.issue=1&rft.spage=13&rft.epage=21&rft.pages=13-21&rft.issn=2049-3614&rft.eissn=2049-3614&rft_id=info:doi/10.1530/EC-12-0008&rft_dat=%3Cpubmed_cross%3E23781299%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b316t-e6f162dfd2e6e093370e82fc14c21c8c5571e5271a70dddca6361bd08c5307cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/23781299&rfr_iscdi=true